世界の肺動脈性肺高血圧症治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Pulmonary Arterial Hypertension Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4864
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、94ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品、ヘルスケア

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、肺動脈性肺高血圧症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（血管拡張薬、ホスホジエステラーゼ5（PDE 5）阻害薬、エンドセリン受容体拮抗薬（ERA）、可溶性グアニル酸シクラーゼ（SGC）刺激薬）、用途別市場規模（病院薬局、ドラッグストア、オンライン薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・肺動脈性肺高血圧症治療の市場動向
・企業の競争状況、市場シェア
・肺動脈性肺高血圧症治療の種類別市場規模（血管拡張薬、ホスホジエステラーゼ5（PDE 5）阻害薬、エンドセリン受容体拮抗薬（ERA）、可溶性グアニル酸シクラーゼ（SGC）刺激薬）
・肺動脈性肺高血圧症治療の用途別市場規模（病院薬局、ドラッグストア、オンライン薬局）
・肺動脈性肺高血圧症治療の北米市場規模2016-2027（アメリカ、カナダ）
・肺動脈性肺高血圧症治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・肺動脈性肺高血圧症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・肺動脈性肺高血圧症治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・肺動脈性肺高血圧症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（GSK、Eli Lilly and Company、Pfizer Inc、Actelion Inc、United Therapeutic Corporation、SteadyMed Ltd、Gilead Sciences, Inc、Teva Pharmaceuticals Inc、Bayer AG）
・結論

Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.

Market Analysis and Insights: Global Pulmonary Arterial Hypertension Treatment Market
The global Pulmonary Arterial Hypertension Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Pulmonary Arterial Hypertension Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Pulmonary Arterial Hypertension Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Pulmonary Arterial Hypertension Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Pulmonary Arterial Hypertension Treatment market.

Global Pulmonary Arterial Hypertension Treatment Scope and Market Size
Pulmonary Arterial Hypertension Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Pulmonary Arterial Hypertension Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Vasodilators
Phosphodiesterase 5 (PDE 5) Inhibitors
Endothelin Receptor Antagonists (ERA)
Soluble Guanylate Cyclase (SGC) Stimulator

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
GSK
Eli Lilly and Company
Pfizer Inc
Actelion Inc
United Therapeutic Corporation
SteadyMed Ltd
Gilead Sciences, Inc
Teva Pharmaceuticals Inc
Bayer AG

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Vasodilators
1.2.3 Phosphodiesterase 5 (PDE 5) Inhibitors
1.2.4 Endothelin Receptor Antagonists (ERA)
1.2.5 Soluble Guanylate Cyclase (SGC) Stimulator
1.3 Market by Application
1.3.1 Global Pulmonary Arterial Hypertension Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Pulmonary Arterial Hypertension Treatment Market Perspective (2016-2027)
2.2 Pulmonary Arterial Hypertension Treatment Growth Trends by Regions
2.2.1 Pulmonary Arterial Hypertension Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Pulmonary Arterial Hypertension Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Pulmonary Arterial Hypertension Treatment Industry Dynamic
2.3.1 Pulmonary Arterial Hypertension Treatment Market Trends
2.3.2 Pulmonary Arterial Hypertension Treatment Market Drivers
2.3.3 Pulmonary Arterial Hypertension Treatment Market Challenges
2.3.4 Pulmonary Arterial Hypertension Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Pulmonary Arterial Hypertension Treatment Players by Revenue
3.1.1 Global Top Pulmonary Arterial Hypertension Treatment Players by Revenue (2016-2021)
3.1.2 Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Pulmonary Arterial Hypertension Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Pulmonary Arterial Hypertension Treatment Revenue
3.4 Global Pulmonary Arterial Hypertension Treatment Market Concentration Ratio
3.4.1 Global Pulmonary Arterial Hypertension Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension Treatment Revenue in 2020
3.5 Pulmonary Arterial Hypertension Treatment Key Players Head office and Area Served
3.6 Key Players Pulmonary Arterial Hypertension Treatment Product Solution and Service
3.7 Date of Enter into Pulmonary Arterial Hypertension Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Pulmonary Arterial Hypertension Treatment Breakdown Data by Type
4.1 Global Pulmonary Arterial Hypertension Treatment Historic Market Size by Type (2016-2021)
4.2 Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Type (2022-2027)

5 Pulmonary Arterial Hypertension Treatment Breakdown Data by Application
5.1 Global Pulmonary Arterial Hypertension Treatment Historic Market Size by Application (2016-2021)
5.2 Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Pulmonary Arterial Hypertension Treatment Market Size (2016-2027)
6.2 North America Pulmonary Arterial Hypertension Treatment Market Size by Type
6.2.1 North America Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2021)
6.2.2 North America Pulmonary Arterial Hypertension Treatment Market Size by Type (2022-2027)
6.2.3 North America Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2027)
6.3 North America Pulmonary Arterial Hypertension Treatment Market Size by Application
6.3.1 North America Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2021)
6.3.2 North America Pulmonary Arterial Hypertension Treatment Market Size by Application (2022-2027)
6.3.3 North America Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2027)
6.4 North America Pulmonary Arterial Hypertension Treatment Market Size by Country
6.4.1 North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2016-2021)
6.4.2 North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Pulmonary Arterial Hypertension Treatment Market Size (2016-2027)
7.2 Europe Pulmonary Arterial Hypertension Treatment Market Size by Type
7.2.1 Europe Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2021)
7.2.2 Europe Pulmonary Arterial Hypertension Treatment Market Size by Type (2022-2027)
7.2.3 Europe Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2027)
7.3 Europe Pulmonary Arterial Hypertension Treatment Market Size by Application
7.3.1 Europe Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2021)
7.3.2 Europe Pulmonary Arterial Hypertension Treatment Market Size by Application (2022-2027)
7.3.3 Europe Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2027)
7.4 Europe Pulmonary Arterial Hypertension Treatment Market Size by Country
7.4.1 Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2016-2021)
7.4.2 Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size (2016-2027)
8.2 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Type
8.2.1 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Application
8.3.1 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Region
8.4.1 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Pulmonary Arterial Hypertension Treatment Market Size (2016-2027)
9.2 Latin America Pulmonary Arterial Hypertension Treatment Market Size by Type
9.2.1 Latin America Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Pulmonary Arterial Hypertension Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2027)
9.3 Latin America Pulmonary Arterial Hypertension Treatment Market Size by Application
9.3.1 Latin America Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Pulmonary Arterial Hypertension Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2027)
9.4 Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country
9.4.1 Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size (2016-2027)
10.2 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Type
10.2.1 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Application
10.3.1 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Country
10.4.1 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Pulmonary Arterial Hypertension Treatment Introduction
11.1.4 GSK Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
11.1.5 GSK Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Details
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Introduction
11.2.4 Eli Lilly and Company Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
11.2.5 Eli Lilly and Company Recent Development
11.3 Pfizer Inc
11.3.1 Pfizer Inc Company Details
11.3.2 Pfizer Inc Business Overview
11.3.3 Pfizer Inc Pulmonary Arterial Hypertension Treatment Introduction
11.3.4 Pfizer Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
11.3.5 Pfizer Inc Recent Development
11.4 Actelion Inc
11.4.1 Actelion Inc Company Details
11.4.2 Actelion Inc Business Overview
11.4.3 Actelion Inc Pulmonary Arterial Hypertension Treatment Introduction
11.4.4 Actelion Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
11.4.5 Actelion Inc Recent Development
11.5 United Therapeutic Corporation
11.5.1 United Therapeutic Corporation Company Details
11.5.2 United Therapeutic Corporation Business Overview
11.5.3 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Introduction
11.5.4 United Therapeutic Corporation Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
11.5.5 United Therapeutic Corporation Recent Development
11.6 SteadyMed Ltd
11.6.1 SteadyMed Ltd Company Details
11.6.2 SteadyMed Ltd Business Overview
11.6.3 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Introduction
11.6.4 SteadyMed Ltd Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
11.6.5 SteadyMed Ltd Recent Development
11.7 Gilead Sciences, Inc
11.7.1 Gilead Sciences, Inc Company Details
11.7.2 Gilead Sciences, Inc Business Overview
11.7.3 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Introduction
11.7.4 Gilead Sciences, Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
11.7.5 Gilead Sciences, Inc Recent Development
11.8 Teva Pharmaceuticals Inc
11.8.1 Teva Pharmaceuticals Inc Company Details
11.8.2 Teva Pharmaceuticals Inc Business Overview
11.8.3 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Introduction
11.8.4 Teva Pharmaceuticals Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
11.8.5 Teva Pharmaceuticals Inc Recent Development
11.9 Bayer AG
11.9.1 Bayer AG Company Details
11.9.2 Bayer AG Business Overview
11.9.3 Bayer AG Pulmonary Arterial Hypertension Treatment Introduction
11.9.4 Bayer AG Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
11.9.5 Bayer AG Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Vasodilators
Table 3. Key Players of Phosphodiesterase 5 (PDE 5) Inhibitors
Table 4. Key Players of Endothelin Receptor Antagonists (ERA)
Table 5. Key Players of Soluble Guanylate Cyclase (SGC) Stimulator
Table 6. Global Pulmonary Arterial Hypertension Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Pulmonary Arterial Hypertension Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Pulmonary Arterial Hypertension Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Pulmonary Arterial Hypertension Treatment Market Share by Regions (2016-2021)
Table 10. Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Pulmonary Arterial Hypertension Treatment Market Share by Regions (2022-2027)
Table 12. Pulmonary Arterial Hypertension Treatment Market Trends
Table 13. Pulmonary Arterial Hypertension Treatment Market Drivers
Table 14. Pulmonary Arterial Hypertension Treatment Market Challenges
Table 15. Pulmonary Arterial Hypertension Treatment Market Restraints
Table 16. Global Pulmonary Arterial Hypertension Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Pulmonary Arterial Hypertension Treatment Market Share by Players (2016-2021)
Table 18. Global Top Pulmonary Arterial Hypertension Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Arterial Hypertension Treatment as of 2020)
Table 19. Ranking of Global Top Pulmonary Arterial Hypertension Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Pulmonary Arterial Hypertension Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Pulmonary Arterial Hypertension Treatment Product Solution and Service
Table 23. Date of Enter into Pulmonary Arterial Hypertension Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Pulmonary Arterial Hypertension Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Pulmonary Arterial Hypertension Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Pulmonary Arterial Hypertension Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Pulmonary Arterial Hypertension Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Pulmonary Arterial Hypertension Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Pulmonary Arterial Hypertension Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Pulmonary Arterial Hypertension Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. GSK Company Details
Table 64. GSK Business Overview
Table 65. GSK Pulmonary Arterial Hypertension Treatment Product
Table 66. GSK Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 67. GSK Recent Development
Table 68. Eli Lilly and Company Company Details
Table 69. Eli Lilly and Company Business Overview
Table 70. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product
Table 71. Eli Lilly and Company Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 72. Eli Lilly and Company Recent Development
Table 73. Pfizer Inc Company Details
Table 74. Pfizer Inc Business Overview
Table 75. Pfizer Inc Pulmonary Arterial Hypertension Treatment Product
Table 76. Pfizer Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 77. Pfizer Inc Recent Development
Table 78. Actelion Inc Company Details
Table 79. Actelion Inc Business Overview
Table 80. Actelion Inc Pulmonary Arterial Hypertension Treatment Product
Table 81. Actelion Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 82. Actelion Inc Recent Development
Table 83. United Therapeutic Corporation Company Details
Table 84. United Therapeutic Corporation Business Overview
Table 85. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product
Table 86. United Therapeutic Corporation Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 87. United Therapeutic Corporation Recent Development
Table 88. SteadyMed Ltd Company Details
Table 89. SteadyMed Ltd Business Overview
Table 90. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product
Table 91. SteadyMed Ltd Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 92. SteadyMed Ltd Recent Development
Table 93. Gilead Sciences, Inc Company Details
Table 94. Gilead Sciences, Inc Business Overview
Table 95. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product
Table 96. Gilead Sciences, Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 97. Gilead Sciences, Inc Recent Development
Table 98. Teva Pharmaceuticals Inc Company Details
Table 99. Teva Pharmaceuticals Inc Business Overview
Table 100. Teva Pharmaceuticals Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 101. Teva Pharmaceuticals Inc Recent Development
Table 102. Bayer AG Company Details
Table 103. Bayer AG Business Overview
Table 104. Bayer AG Pulmonary Arterial Hypertension Treatment Product
Table 105. Bayer AG Revenue in Pulmonary Arterial Hypertension Treatment Business (2016-2021) & (US$ Million)
Table 106. Bayer AG Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Pulmonary Arterial Hypertension Treatment Market Share by Type: 2020 VS 2027
Figure 2. Vasodilators Features
Figure 3. Phosphodiesterase 5 (PDE 5) Inhibitors Features
Figure 4. Endothelin Receptor Antagonists (ERA) Features
Figure 5. Soluble Guanylate Cyclase (SGC) Stimulator Features
Figure 6. Global Pulmonary Arterial Hypertension Treatment Market Share by Application: 2020 VS 2027
Figure 7. Hospital Pharmacies Case Studies
Figure 8. Retail Pharmacies Case Studies
Figure 9. Online Pharmacies Case Studies
Figure 10. Pulmonary Arterial Hypertension Treatment Report Years Considered
Figure 11. Global Pulmonary Arterial Hypertension Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Pulmonary Arterial Hypertension Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Pulmonary Arterial Hypertension Treatment Market Share by Regions: 2020 VS 2027
Figure 14. Global Pulmonary Arterial Hypertension Treatment Market Share by Regions (2022-2027)
Figure 15. Global Pulmonary Arterial Hypertension Treatment Market Share by Players in 2020
Figure 16. Global Top Pulmonary Arterial Hypertension Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Arterial Hypertension Treatment as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Pulmonary Arterial Hypertension Treatment Revenue in 2020
Figure 18. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2016-2021)
Figure 19. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2022-2027)
Figure 20. North America Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Pulmonary Arterial Hypertension Treatment Market Share by Type (2016-2027)
Figure 22. North America Pulmonary Arterial Hypertension Treatment Market Share by Application (2016-2027)
Figure 23. North America Pulmonary Arterial Hypertension Treatment Market Share by Country (2016-2027)
Figure 24. United States Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Pulmonary Arterial Hypertension Treatment Market Share by Type (2016-2027)
Figure 28. Europe Pulmonary Arterial Hypertension Treatment Market Share by Application (2016-2027)
Figure 29. Europe Pulmonary Arterial Hypertension Treatment Market Share by Country (2016-2027)
Figure 30. Germany Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Share by Region (2016-2027)
Figure 40. China Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Pulmonary Arterial Hypertension Treatment Market Share by Type (2016-2027)
Figure 48. Latin America Pulmonary Arterial Hypertension Treatment Market Share by Application (2016-2027)
Figure 49. Latin America Pulmonary Arterial Hypertension Treatment Market Share by Country (2016-2027)
Figure 50. Mexico Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Share by Country (2016-2027)
Figure 56. Turkey Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. GSK Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
Figure 60. Eli Lilly and Company Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
Figure 61. Pfizer Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
Figure 62. Actelion Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
Figure 63. United Therapeutic Corporation Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
Figure 64. SteadyMed Ltd Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
Figure 65. Gilead Sciences, Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
Figure 66. Teva Pharmaceuticals Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
Figure 67. Bayer AG Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

Global Pulmonary Arterial Hypertension (PAH) Market Size, Status and Forecast 2021-2027
QYR2104Z4863 2021年4月 90Pages
QYResearch社発行の本調査資料では、肺動脈性肺高血圧症（PAH）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（プロスタサイクリン＆プロスタサイクリン類似体、SGC刺激剤、ERA、PDE-5）、用途別市場規模（病院、診療所）、主要地域別...

世界の慢性血栓塞栓性肺高血圧症（CTEPH）市場規模・現状・予測（2021年-2027年）

Global Chronic Thromboembolic Pulmonary Hypertension Market Size, Status and Forecast 2021-2027
QYR2104Z1329 2021年4月 99Pages
QYResearch社発行の本調査資料では、慢性血栓塞栓性肺高血圧症（CTEPH）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（経胸壁心エコー図（TTE）、換気灌流（V / Q）スキャン、肺血管造影、心臓カテーテル検査、コンピューター断層撮影...

世界の高眼圧症治療市場規模・現状・予測（2021年-2027年）

Global Ocular Hypertension Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4224 2021年4月 98Pages
QYResearch社発行の本調査資料では、高眼圧症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（高眼圧症、緑内障）、用途別市場規模（病院、専門クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国...

世界の高血圧・心不全治療市場規模・現状・予測（2021年-2027年）

Global Hypertension and Heart Failure Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3000 2021年4月 93Pages
QYResearch社発行の本調査資料では、高血圧・心不全治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（利尿薬、β遮断薬、エース阻害薬、α遮断薬、その他）、用途別市場規模（男性、女性）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジ...

世界の特発性頭蓋内圧亢進症治療市場規模・現状・予測（2021年-2027年）

Global Idiopathic Intracranial Hypertension Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3017 2021年4月 127Pages
QYResearch社発行の本調査資料では、特発性頭蓋内圧亢進症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アセタゾラミド、メタゾラミド、フロセミド、トピラマート、その他）、用途別市場規模（病院、クリニック、外来手術センター）、主要地域...

世界の3D動脈スピンラベリング（3D ASL）市場規模・現状・予測（2021年-2027年）

Global 3D Arterial Spin Labeling (3D ASL) Market Size, Status and Forecast 2021-2027
QYR2104Z6125 2021年4月 96Pages
QYResearch社発行の本調査資料では、3D動脈スピンラベリング（3D ASL）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（キャッスル（CASL）、PASL）、用途別市場規模（腫瘍、脳血管障害、神経変性疾患、パーキンソン病）、主要地域別...

世界の末梢動脈疾患（PAD）治療薬市場規模・現状・予測（2021年-2027年）

Global Peripheral Arterial Disease (PAD) Drugs Market Size, Status and Forecast 2021-2027
QYR2104Z4518 2021年4月 93Pages
QYResearch社発行の本調査資料では、末梢動脈疾患（PAD）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（クロピドグレル（Plavix）、プラスグレル（Effient）、チカグレロル（Brilinta）、ボラパクサール（Zonti...

世界の慢性閉塞性肺疾患（COPD）市場規模・現状・予測（2021年-2027年）

Global Chronic Obstructive Pulmonary Disease Market Size, Status and Forecast 2021-2027
QYR2104Z1323 2021年4月 98Pages
QYResearch社発行の本調査資料では、慢性閉塞性肺疾患（COPD）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（気管支拡張薬、糖質コルチコイド、その他）、用途別市場規模（予防、診断、治療）、主要地域別市場規模（北米、アメリカ、ヨーロッパ...

世界の末梢動脈疾患（PAD）治療薬市場規模・現状・予測（2021年-2027年）

Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z4519 2021年4月 99Pages
QYResearch社発行の本調査資料では、末梢動脈疾患（PAD）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（抗血小板薬、二重抗血小板療法薬、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロ...

世界の肺水腫市場規模・現状・予測（2021年-2027年）

Global Pulmonary Edema Market Size, Status and Forecast 2021-2027
QYR2104Z4865 2021年4月 92Pages
QYResearch社発行の本調査資料では、肺水腫のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（診断、治療）、用途別市場規模（病院＆診療所、学術機関、ドラッグストア）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、...

世界の肺動脈性肺高血圧症（PAH）市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Pulmonary Arterial Hypertension (PAH) Market The global Pulmonary Arterial Hypertension (PAH) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and…
世界の慢性血栓塞栓性肺高血圧症（CTEPH）市場規模・現状・予測（2021年-2027年） Chronic thromboembolic pulmonary hypertension is observed to be one of the leading causes of severe pulmonary hypertension. It is a type of clinical condition in which pulmonary vascular resistance increases giving rise to pulmonary hypertension and progressive heart failure. According to World Heal…
世界の高血圧・心不全治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Hypertension and Heart Failure Treatment Market The global Hypertension and Heart Failure Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analys…
世界の高眼圧症治療市場規模・現状・予測（2021年-2027年） Ocular hypertension is caused by poor drainage of the fluid inside the eye. Essentially, this means that too much fluid enters the eye without being drained, causing high amount of pressure to build up. Market Analysis and Insights: Global Ocular Hypertension Treatment Market The global Ocular Hyper…
世界の特発性頭蓋内圧亢進症治療市場規模・現状・予測（2021年-2027年） Idiopathic intracranial hypertension is characterized by a buildup of the cerebrospinal fluid causing increase in the blood volume in vessels surrounding the brain and increase in brain swelling. The increase in salt intake causes water retention in the body together with fat adding on to the calori…